

DWS Health and Wellness Fund Total Holdings as of 11/29/24

	Cusip/Sedol	Ticker	Security Name	Portfolio Weight(%)	Principal Amount	Final Maturity Date	Market Value	Market Price	Coupon Rate
1	532457108	LLY	ELI LILLY + CO	11.097%	40,007.00		31,819,567.45	795.35	0.00
2	91324P102	UNH	UNITEDHEALTH GROUP INC	10.539%	49,523.00		30,218,934.60	610.20	0.00
3	101137107	BSX	BOSTON SCIENTIFIC CORP	4.131%	130,656.00		11,845,272.96	90.66	0.00
4	58933Y105	MRK	MERCK + CO. INC.	3.755%	105,919.00		10,765,607.16	101.64	0.00
5	478160104	JNJ	JOHNSON + JOHNSON W/D	3.670%	67,885.00		10,522,853.85	155.01	0.00
6	46120E602	ISRG	INTUITIVE SURGICAL INC	3.546%	18,759.00		10,167,378.00	542.00	0.00
7	00287Y109	ABBV	ABBVIE INC	3.514%	55,080.00		10,075,784.40	182.93	0.00
8	883556102	TMO	THERMO FISHER SCIENTIFIC INC	3.491%	18,898.00		10,008,947.74	529.63	0.00
9	670100205	NVO	NOVO NORDISK A/S SPONS ADR	3.267%	87,710.00		9,367,428.00	106.80	0.00
10	002824100	ABT	ABBOTT LABORATORIES	3.069%	74,101.00		8,800,975.77	118.77	0.00
11	863667101	SYK	STRYKER CORP	2.955%	21,604.00		8,472,008.60	392.15	0.00
12	235851102	DHR	DANAHER CORP	2.620%	31,338.00		7,511,405.22	239.69	0.00
13	92532F100	VRTX	VERTEX PHARMACEUTICALS INC	2.593%	15,881.00		7,434,372.53	468.13	0.00
14	046353108	AZN	ASTRAZENECA PLC SPONS ADR	2.310%	97,946.00		6,623,108.52	67.62	0.00
15	031162100	AMGN	AMGEN INC	2.061%	20,893.00		5,910,002.91	282.87	0.00
16	58155Q103	MCK	MCKESSON CORP	1.797%	8,200.00		5,153,700.00	628.50	0.00
17	375558103	GILD	GILEAD SCIENCES INC	1.629%	50,450.00		4,670,661.00	92.58	0.00
18	75886F107	REGN	REGENERON PHARMACEUTICALS	1.618%	6,185.00		4,640,110.70	750.22	0.00
19	66987V109	NVS	NOVARTIS AG SPONSORED ADR	1.608%	43,600.00		4,611,572.00	105.77	0.00
20	98978V103	ZTS	ZOETIS INC	1.556%	25,456.00		4,461,164.00	175.25	0.00
21	BTN1Y11	MDT	MEDTRONIC PLC	1.542%	51,088.00		4,421,155.52	86.54	0.00
22	075887109	BDX	BECTON DICKINSON AND CO	1.261%	16,300.00		3,616,970.00	221.90	0.00
23	BJXBP41	ALC	ALCON INC	1.208%	38,997.00		3,464,883.45	88.85	0.00
24	03073E105	COR	CENCORA INC	1.177%	13,414.00		3,374,291.70	251.55	0.00
25	00846U101	A	AGILENT TECHNOLOGIES INC	1.001%	20,806.00		2,870,603.82	137.97	0.00
26	717081103	PFE	PFIZER INC	0.998%	109,170.00		2,861,345.70	26.21	0.00
27	110122108	BMY	BRISTOL MYERS SQUIBB CO	0.991%	47,960.00		2,840,191.20	59.22	0.00
28	750491102	RDNT	RADNET INC	0.986%	34,587.00		2,827,833.12	81.76	0.00
29	761152107	RMD	RESMED INC	0.855%	9,847.00		2,452,099.94	249.02	0.00
30	457669307	INSM	INSMED INC	0.855%	32,610.00		2,450,967.60	75.16	0.00
31	46266C105	IQV	IQVIA HOLDINGS INC	0.841%	12,000.00		2,410,080.00	200.84	0.00
32	436440101	HOLX	HOLOGIC INC	0.817%	29,477.00		2,343,421.50	79.50	0.00
33	14149Y108	CAH	CARDINAL HEALTH INC	0.763%	17,900.00		2,188,096.00	122.24	0.00
34	955306105	WST	WEST PHARMACEUTICAL SERVICES	0.763%	6,715.00		2,186,941.20	325.68	0.00
35	04016X101	ARGX	ARGENX SE ADR	0.715%	3,323.00		2,048,795.65	616.55	0.00
36	252131107	DXCM	DEXCOM INC	0.710%	26,108.00		2,036,162.92	77.99	0.00
37	80105N105	SNY	SANOFI ADR	0.679%	40,150.00		1,946,873.50	48.49	0.00
38	09062X103	BIIB	BIOGEN INC	0.658%	11,750.00		1,887,402.50	160.63	0.00
39	70975L107	PEN	PENUMBRA INC	0.643%	7,557.00		1,844,814.84	244.12	0.00
40	36266G107	GEHC	GE HEALTHCARE TECHNOLOGY	0.595%	20,500.00		1,706,010.00	83.22	0.00
41	28176E108	EW	EDWARDS LIFESCIENCES CORP	0.567%	22,796.00		1,626,494.60	71.35	0.00
42	071813109	BAX	BAXTER INTERNATIONAL INC	0.562%	47,800.00		1,611,338.00	33.71	0.00
43	02043Q107	ALNY	ALNYLAM PHARMACEUTICALS INC	0.556%	6,301.00		1,594,594.07	253.07	0.00
44	216648501	COO	COOPER COS INC/THE	0.539%	14,800.00		1,546,008.00	104.46	0.00
45	64125C109	NBIX	NEUROCRINE BIOSCIENCES INC	0.537%	12,137.00		1,538,364.75	126.75	0.00
46	45784P101	PODD	INSULET CORP	0.524%	5,632.00		1,502,504.96	266.78	0.00
47	45168D104	IDXX	IDEXX LABORATORIES INC	0.484%	3,289.00		1,387,135.75	421.75	0.00
48	15135B101	CNC	CENTENE CORP	0.466%	22,274.00		1,336,440.00	60.00	0.00
49	922475108	VEEV	VEEVA SYSTEMS INC CLASS A	0.438%	5,518.00		1,257,276.30	227.85	0.00
50	09627Y109	BPMC	BLUEPRINT MEDICINES CORP	0.429%	12,762.00		1,230,001.56	96.38	0.00
51	46116X101	ITCI	INTRA CELLULAR THERAPIES INC	0.415%	13,882.00		1,188,993.30	85.65	0.00
					-,		,,		

	Cusip/Sedol	Ticker	Security Name	Portfolio Weight(%)	Principal Amount	Final Maturity Date	Market Value	Market Price	Coupon Rate
52	941848103	WAT	WATERS CORP	0.362%	2,700.00		1,038,744.00	384.72	0.00
53	09061G101	BMRN	BIOMARIN PHARMACEUTICAL INC	0.360%	15,642.00		1,032,841.26	66.03	0.00
54	981DNHII5		CENTRAL CASH MANAGEMENT FD	0.352%	1,008,072.52	12/01/2050	1,008,072.52	100.00	0.00
55	45337C102	INCY	INCYTE CORP	0.345%	13,279.00		990,480.61	74.59	0.00
56	444859102	HUM	HUMANA INC	0.343%	3,316.00		982,796.08	296.38	0.00
57	90400D108	RARE	ULTRAGENYX PHARMACEUTICAL IN	0.342%	20,571.00		979,796.73	47.63	0.00
58	74276R102	PRVA	PRIVIA HEALTH GROUP INC	0.326%	43,532.00		935,067.36	21.48	0.00
59	30063P105	EXAS	EXACT SCIENCES CORP	0.312%	14,422.00		895,317.76	62.08	0.00
60	504922105	LH	LABCORP HOLDINGS INC	0.310%	3,690.00		889,880.40	241.16	0.00
61	86881A100	SGRY	SURGERY PARTNERS INC	0.304%	36,540.00		871,113.60	23.84	0.00
62	379577208	GMED	GLOBUS MEDICAL INC A	0.257%	8,600.00		736,246.00	85.61	0.00
63	09073M104	TECH	BIO TECHNE CORP	0.255%	9,700.00		730,992.00	75.36	0.00
64	452327109	ILMN	ILLUMINA INC	0.246%	4,891.00		705,037.65	144.15	0.00
65	457730109	INSP	INSPIRE MEDICAL SYSTEMS INC	0.237%	3,524.00		679,286.24	192.76	0.00
66	45332Y109	NARI	INARI MEDICAL INC	0.230%	12,712.00		660,007.04	51.92	0.00
67	759916109	RGEN	REPLIGEN CORP	0.210%	4,000.00		602,160.00	150.54	0.00
68	05352A100	AVTR	AVANTOR INC	0.186%	25,351.00		533,892.06	21.06	0.00
69	60770K107	MRNA	MODERNA INC	0.156%	10,406.00		448,082.36	43.06	0.00
70	04335A105	ARVN	ARVINAS INC	0.155%	16,633.00		444,433.76	26.72	0.00
71	799926100	SDZNY	SANDOZ GROUP AG ADR	0.138%	8,700.00		396,667.80	45.59	0.00
72	30233G209	EYPT	EYEPOINT PHARMACEUTICALS INC	0.070%	22,600.00		200,010.00	8.85	0.00
73	088786108	BCYC	BICYCLE THERAPEUTICS PLC ADR	0.057%	8,070.00		164,628.00	20.40	0.00
74	03753U106	APLS	APELLIS PHARMACEUTICALS INC	0.040%	3,400.00		115,362.00	33.93	0.00
75	CASHUSD		Us Dollar	0.003%			10,000.00		

The portfolio holdings information above reflects the portfolio of the fund as of the stated date. The holdings are presented for informational purposes only and should not be considered a replacement for portfolio holdings reported and/or filed for regulatory purposes. The holdings information is unaudited and holdings are subject to change. Portfolio Weight (%) refers to all securities in the portfolio.

Because different calculation methods are used, the portfolio holdings information above may be different for the same period contained in the fund's annual and semiannual shareholder reports o first and third quarter reports filed with the Securities and Exchange Commission on Form N-PORT. Additionally, this data may differ from any holdings information found on firms' marketing materials.

Before investing, carefully consider the fund's investment objective, risks, charges and expenses. There is no assurance that the fund willachieve its investment objective. The fund is subject to numerous risks, including investment risks.

For DWS open-end funds, please obtain a prospectus. To obtain an open-end fund summary prospectus, if available, or prospectus, download one from fundsus.dws.com, talk to your financial representative or call (800) 728-3337. The summary prospectus and prospectus contain important information about the fund, including information regarding the fund's objective, risks, charges and expenses. Please read the prospectus carefully before you invest.

Closed-end funds, unlike open-end funds, are not continuously offered. There is a one-time public offering and once issued, shares of closed-end funds are sold in the open market through a stock exchange. Shares of closed-end funds frequently trade at a discount to net asset value. The price of the fund's shares is determined by a number of factors, several of which are beyond the control of the fund. Therefore, the fund cannot predict whether its shares will trade at, below or above net asset value. Information on the investment objective, investment policies and principal risks for each DWS closed-end fund appears in the fund's most recent annual report. For further information on DWS closed-end funds, call (800) 349-4281.

War, terrorism, sanctions, economic uncertainty, trade disputes, public health crises and related geopolitical events have led and, in the future, may lead to significant disruptions in U.S. and world economies and markets, which may lead to increased market volatility and may have significant adverse effects on the fund and its investments.

Fund risk: Stocks may decline in value. Any fund that concentrates in a particular segment of the market will generally be more volatile than a fund that invests more broadly. Investing in foreign securities presents certain risks, such as currency fluctuations, political and economic changes, and market risks. Small company stocks tend to be more volatile than medium-sized or large company stocks. This fund is non-diversified and can take larger positions in fewer issues, increasing its potential risk. The fund may lend securities to approved institutions. Please read the prospectus for details. Consider the investment objective, risks, charges and expenses carefully before investing. For a summary prospectus, or prospectus that contains this and other information, download one from www.dws.com or talk to your financial representative. Read the prospectus carefully before investing.

The brand DWS represents DWS Group GmbH & Co. KGaA and any of its subsidiaries such as DWS Distributors, Inc., which offers investment products, or DWS Investment Management Americas, Inc. and RREEF America L.L.C., which offer advisory services.

Investment products: No bank guarantee | Not FDIC insured | May lose value

DWS Distributors, Inc.

222 South Riverside Plaza Chicago, IL 60606-5808 fundsus.dws.com e-mail service@dws.com Tel (800) 621-1148 TDD (800) 972-3006

NOT FDIC INSURED MAY LOSE VALUE NO BANK GUARANTEE NOT A DEPOSIT NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY

R-005024-12 (6/24)